Adamis Pharmaceuticals Corporation (ADMP)
| Market Cap | 157.11M |
| Revenue (ttm) | 18.43M |
| Net Income (ttm) | -34.71M |
| Shares Out | 76.04M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $1.12 |
| Previous Close | $1.11 |
| Change ($) | 0.01 |
| Change (%) | 0.90% |
| Day's Open | 1.11 |
| Day's Range | 1.05 - 1.17 |
| Day's Volume | 5,555,431 |
| 52-Week Range | 0.27 - 2.34 |
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent application...
SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its comm...
SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in vari...
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in vari...
SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer fo...
Adamis Pharmaceuticals finished 2020 with some Malheur with the company receiving its second CRL for ZIMHI. However, the company is a making a strong comeback thus far in 2021. Adamis plans to...
Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science ...
Adamis Pharma (ADMP) stock is taking off on Friday after a week of positive news for the company, including a deal with Walgreens. The post ADMP Stock: 4 Things to Know About Adamis Pharma Tod...
SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members o...
Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.
Adamis Pharma (ADMP) stock is taking off on Wednesday following news of its possible treatment for the novel coronavirus. The post ADMP Stock Alert: The Covid-19 Treatment News That Has Adamis...
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the inv...
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th...
Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript
Adamis (ADMP) delivered earnings and revenue surprises of -150.00% and -47.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a b...
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, ...
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...
SAN DIEGO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was in...
Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q2 2020 Results - Earnings Call Transcript
Adamis (ADMP) delivered earnings and revenue surprises of -85.71% and -21.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provid...
SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) fil...
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting A...
Adamis Pharmaceuticals Corp (NASDAQ: ADMP) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of co...
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license to commercialize Tempol, a novel patented investigation...
Adamis recently reported their Q1 earnings with a miss on EPS and revenue. The COVID-19 pandemic has had a significant impact on the company's US Compounding sales.
Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2020 Results - Earnings Call Transcript
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a busi...
SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) I...
Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SAN DIEGO, April 23, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Int...
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ha...
Adamis Pharmaceuticals: Trying To Find A Course Of Action
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Payc...
SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ...
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement...
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...
SAN DIEGO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that an article entitled “Comparative Pharmacokinetic Analysis of ...
Adamis Pharmaceuticals Corp (ADMP) CEO Dennis Carlo on Q3 2019 Results - Earnings Call Transcript
Adamis: Overdue ZIMHI Decision Puts The Brakes On Stock's Downward Trend
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that as of the close of business today, Adamis has not received an...
About ADMP
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| CEO Dennis Carlo | Employees 131 |
| Stock Exchange NASDAQ | Ticker Symbol ADMP |
Financial Performance
In 2019, ADMP's revenue was $22.11 million, an increase of 46.58% compared to the previous year's $15.09 million. Losses were -$29.31 million, -24.87% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for ADMP stock is "Buy." The 12-month stock price forecast is 1.00, which is a decrease of -10.71% from the latest price.